Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).
Anna Maria Di Giacomo(University of Siena), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Luca Galli(University of Pisa), Francesco De Rosa(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Paola Savoia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Antonio Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ruggero Ridolfi, Francesco Cognetti(Apple (Israel)), Michele Guida(Istituto Tumori Bari), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Sabino Strippoli(Istituto Tumori Bari), Paola Queirolo, Massimo Aglietta(Candiolo Cancer Institute), Maria Grazia Bernengo(University of Turin), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Gaetana Rinaldi(AOL (United States)), Mario Mandalà(University of Perugia)
Cited by 15
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k